title: Decreased alveolar macrophage apoptosis is associated with increased pulmonary inflammation in a murine model of pneumococcal pneumonia.
abstract: Regulation of the inflammatory infiltrate is critical to the successful outcome of pneumonia. Alveolar macrophage apoptosis is a feature of pneumococcal infection and aids disease resolution. The host benefits of macrophage apoptosis during the innate response to bacterial infection are incompletely defined. Because NO is required for optimal macrophage apoptosis during pneumococcal infection, we have explored the role of macrophage apoptosis in regulating inflammatory responses during pneumococcal pneumonia, using inducible NO synthase (iNOS)-deficient mice. iNOS(-/-) mice demonstrated decreased numbers of apoptotic macrophages as compared with wild-type C57BL/6 mice following pneumococcal challenge, greater recruitment of neutrophils to the lung and enhanced expression of TNF-alpha. Pharmacologic inhibition of iNOS produced similar results. Greater pulmonary inflammation was associated with greater levels of early bacteremia, IL-6 production, lung inflammation, and mortality within the first 48 h in iNOS(-/-) mice. Labeled apoptotic alveolar macrophages were phagocytosed by resident macrophages in the lung and intratracheal instillation of exogenous apoptotic macrophages decreased neutrophil recruitment in iNOS(-/-) mice and decreased TNF-alpha mRNA in lungs and protein in bronchial alveolar lavage, as well as chemokines and cytokines including IL-6. These changes were associated with a lower probability of mice becoming bacteremic. This demonstrates the potential of apoptotic macrophages to down-regulate the inflammatory response and for the first time in vivo demonstrates that clearance of apoptotic macrophages decreases neutrophil recruitment and invasive bacterial disease during pneumonia.
authors.affiliation: School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, United Kingdom.
authors.forename: Helen M
authors.initials: HM
authors.lastname: Marriott
authors.forename: Paul G
authors.initials: PG
authors.lastname: Hellewell
authors.forename: Simon S
authors.initials: SS
authors.lastname: Cross
authors.forename: Paul G
authors.initials: PG
authors.lastname: Ince
authors.forename: Moira K B
authors.initials: MK
authors.lastname: Whyte
authors.forename: David H
authors.initials: DH
authors.lastname: Dockrell
mesh_terms: D000818:Animals; D017209:Apoptosis; D016470:Bacteremia / Q000201:enzymology / Q000235:genetics / Q000276:immunology; D015415:Biomarkers / Q000032:analysis; D004195:Disease Models, Animal; D008168:Lung / Q000201:enzymology / Q000276:immunology* / Q000382:microbiology; D016676:Macrophages, Alveolar / Q000201:enzymology / Q000502:physiology*; D051379:Mice; D008817:Mice, Mutant Strains; D009504:Neutrophils / Q000201:enzymology / Q000276:immunology; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors / Q000172:deficiency* / Q000235:genetics; D011018:Pneumonia, Pneumococcal / Q000201:enzymology / Q000235:genetics / Q000276:immunology*; D013296:Streptococcus pneumoniae / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism
chemical_list: D015415:Biomarkers; D014409:Tumor Necrosis Factor-alpha; D052247:Nitric Oxide Synthase Type II